enGene Holdings (Forbion European Acquisition) ^{Priced, Nasdaq: ENGN}

Forbion European Acquisition Corp. is a newly organized blank check company. While we may pursue an initial business combination opportunity in any business, industry, sector or geographical location, we intend to capitalize on the ability of our management team to identify promising late-stage opportunities in the life sciences industry in Europe. Founded in 2006, Forbion (“Forbion”) is a life sciences specialist venture fund manager with headquarters in Naarden, the Netherlands, and offices in Munich, Germany, and Singapore. Forbion has established itself as one of the leading brands within the European life sciences industry, supported by a successful track record and strong reputation with co-investors, entrepreneurs, and large pharmaceutical companies (“large pharma”). With 32 employees and a large network of dedicated advisors, Forbion boasts one of the largest teams of specialist investors in Europe, combining investment expertise in private and public markets with hands-on operational expertise in drug development, clinical development, and commercialization.